Allergan: Europe Halts Esmya Prescriptions Amid Liver Risk Probe

The European Medicines Agency advised that no new patients take Esmya due to potential links to liver injury. The decision could stymie AGN's attempt to seek FDA approval for Esmya in the U.S.